Fund moves
4.5%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ELAN · NYSE · Pharmaceuticals
Elanco (ELAN) · oqro.io/stocks/ELAN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$25.74−0.55 (−2.09%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Elanco was filed in the last 90 days. The latest on record was on Aug 21, 2026.
Since 2018, Elanco insiders reported 84 open-market purchases and 2 sales on Forms 4 and 5, with purchases in 9 different years, most recently 2026.
In the last 90 days, 1 insider of Elanco (ELAN) reported 1 open-market sale worth $100K in total on SEC Form 4. The largest seller by value was Timothy J Bettington, with $100K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Elanco (ELAN) was disclosed by a member of Congress in the last 12 months.
Elanco's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+21.2% (+$4.50) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $21.24 on Nov 20, 2025 to $25.74 on Nov 20, 2026 (+21.2%). Disclosed in this range: 10 insider trades, 1 pre-arranged insider sale, 0 Congress trades, and 36 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceuticals company based in Greenfield, Indiana.
Last 12 months
+21.2%
Market value
$12.9B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 32.9M shares sold short (6.6% of shares outstanding), +5.8% vs the previous count, 7.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$4.71B
+6.2% vs the year before
Net income, fiscal 2025
−$232M
A loss for the year
Shares outstanding
500M
As of Nov 4, 2026
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Timothy J. Bettington (Officer) plans to sell ~$100K of Elanco
Planned, from payInsider buying
Their largest buy since 2018Traded Aug 20 · filed 1 day later
Since the trade +9.3% · S&P 500 −9.5% · to Nov 20
Bought 12% below the 52-week high, RSI 46, 10 points ahead of the S&P 500 over 3 months
An Elanco director paid $936K out of pocket for Elanco shares. 4 other people at Elanco bought some too, in the same month. It was the first purchase in 8 months.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last results
Nov 6, 2026
Within the 30 days after it, until Dec 6, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
79%
58 of 73 insider purchases since 2018 came within 30 days after a results announcement
From Elanco's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Elanco's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Against the S&P 500 over the year
Since Nov 19, 2025, ELAN is up 19.9% and the index fund is up 4.1%: 16 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ELAN moves
Beta 1.3 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Insiders of Elanco reported 84 open-market purchases and 2 sales since 2018; purchases in 9 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $1.67M7×7 trades | $100K1×1 trade |
| 2025 | $1.33M6×6 trades | — |
| 2024 | $2.23M6×6 trades | — |
| 2023 | $350K4×4 trades | — |
| 2022 | $1.86M10×10 trades | — |
| 2021 | $2.29M9×9 trades | — |
| 2020 | $1.7M13×13 trades | $1.63B1×1 trade |
| 2019 | $4.08M18×18 trades | — |
| 2018 | $1.75M11×11 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
FMR LLC
13G · passive · Amended · 66.2M shares · filed Nov 5, 2026
Dodge & Cox
13G · passive · Amended · 61.4M shares · filed Nov 12, 2026
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
Revenue
$1.26B
+11.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$408M
This quarter $156M, a year earlier $127M
Net debt
$2.98B
Debt $3.45B, cash $465M, at Sep 30, 2026
Net income, last 12 months
−$147M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 6, 2026.
Revenue and earnings history, 10 fiscal yearsEarnings dates and the stock's moves
Off-exchange trading: 41.2% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (27.7% on ATS, 13.5% with other brokers), below its 26-week average of 44.0%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: INTELLIGENT CROSS LLC (13.9%), MS TRAJECTORY CROSS (ATS-1) (11.2%), LEVEL ATS (9.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
· Administrative proceeding · 34-104992
Administrative proceeding: Elanco Animal Health Inc.· Administrative proceeding · 34-104419
Administrative proceeding: Elanco Animal Health Inc.· Administrative proceeding · 34-102292
Administrative proceeding: Elanco Animal Health Inc.· Administrative proceeding · 33-11326
SEC Charges Indiana-Based Animal Health Products Company With Antifraud ViolationsThe SEC wrote: The Securities and Exchange Commission today announced antifraud charges against Elanco Animal Health Inc. for misleading investors when it made statements about its revenue growth and end-user demand without also disclosing its reliance on certain quarter-end sales incentives that were necessary to achieve that revenue and caused its distributors to purchase goods in excess of existing end-user demand.
The SEC says the respondent agreed to settle without admitting or denying the allegations or findings.
These are SEC announcements. Charges in a complaint or an order instituting proceedings are allegations; quoted text is the SEC's own wording. Listed when the company is named as a respondent under its exact legal name, or by the CIK or ticker the SEC states. Actions against subsidiaries or former names are not listed. Source: SEC.gov litigation releases, administrative proceedings and trading suspensions, checked Nov 19, 2026.
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 25, 2025. Read the filing
All 47 risk factor headings match the year before, give or take wording.
Information pertaining to certain legal proceedings is provided in Item 8. Financial Statements and Supplementary Data — Note 16. Commitments and Contingencies and is incorporated by reference herein.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 6, 2026. Quarterly reports are not audited. Read the filing
+14% on the same quarter a year earlier ($533M)
+17% on the same quarter a year earlier ($289M)
−7.4% on the same quarter a year earlier ($217M)
+4.6% on the same quarter a year earlier ($87M)
+136% on the same quarter a year earlier ($11M)
The company also reports Farm Animal: ($631M), which group lines above and are not added again.
+11% on the same quarter a year earlier ($590M)
+12% on the same quarter a year earlier ($547M)
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
+7.3% on the year before ($2.14B)
+12% on the year before ($1.01B)
+7.8% on the year before ($796M)
+3.6% on the year before ($366M)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
Elanco is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve. Our diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health) and cattle, poultry, swine and sheep (collectively, farm animal). Our purpose – making life better for animals makes life better – inspires us to Go Beyond for animals, our customers, our people and society.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026 and Form 10-Q filed Nov 6, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
+15% on the year before ($46M)
$81M the year before
The company also reports Farm Animal: ($2.36B), which group lines above and are not added again.
+3.2% on the year before ($2.4B)
+9.7% on the year before ($2.04B)
And 17 more headings in the filing.
0 certified in FY2026 Q3, vs 3 a year earlier.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.